About Sumitomo Pharma R&D Capabilities
Position We Aspire to Establish by 2033
Establish position as a Global Specialized Player (GSP)
We will establish a unique position globally by contributing to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products and Regenerative Medicine/Cell Therapy, focusing on the Psychiatry & Neurology, and Oncology areas as our priority disease areas.
-
-
Small molecule
Molecular design/synthesis based on accumulated experience/know-how
-
Regenerative medicine/cell therapy
Know-how acquired by pioneering initiatives
-
Other modalities
Pursuit of optimal modalities
-
Psychiatry & Neurology Area
Diverse approaches to innovate
the conventional treatment system- Our core area
- Accumulated data, experience, and know-how
-
Oncology Area
Distinguished products to innovate
standard treatment- Carefully selected R&D pipeline
- Unique fundamentals for drug discovery
-
Other Areas
Deliver value to patients by
leveraging our assets- Women’s health issues, urological diseases, diabetes
- Rare diseases, infectious diseases
-
Psychiatry & Neurology Area
The Psychiatry & Neurology Area is a disease area with high unmet medical needs and a significant impact on healthy life expectancy. We have a rich track record and expertise in the research and development of numerous products over the years. In addition to the drug discovery of small molecule, we are also challenging new modalities such as Regenerative Medicine/Cell Therapy Business and Frontier Business.
We are engaged in drug discovery using advanced technologies (in silico, biomarkers, iPS cells, etc.), on the strength of our experience with continuous product creation and our R&D know-how. We conduct competitive drug discovery research based on our proprietary drug discovery technology platform, which we have built by incorporating cutting-edge technologies.
-
Number of compounds under development （Small molecule）
0
As of January 31, 2025
Oncology Area
Through our research and development activities to date, we have gained various insights, strengthened our drug discovery capabilities, and created multiple development pipelines with unique characteristics. Capitalizing on these strengths, we will continue to focus on research and development in the oncology area, which has high unmet medical needs.
In drug discovery, we aim to create innovative new drugs by enhancing our competitiveness through initiatives such as the development of modalities using our own novel technologies and joint research with academia. We will also strengthen collaboration between research and development and engage in translational research* to increase the probability of success.
- *Translational research: Research that links research results to patient treatment in clinical development
-
Number of compounds under development
0
As of January 31, 2025
The Field of Regenerative Medicine and Cell Therapy
This is a field with great market potential due to our ability to take advantage of the accumulated research and comprehensive capabilities built up by Sumitomo Pharma Group over many years, and to approach the treatment of diseases that cannot be solved by existing therapeutic agents.
Our Group aims to provide new value in the regenerative and cell medicine field by leveraging our strengths in networking through open innovation with academia, startup companies, and other industries. We utilize our accumulated technologies for the practical application of iPS cells, such as differentiation induction technology from pluripotent stem cells, and our extensive manufacturing capabilities, methods, infrastructure, and human resources related to cell production. Specifically, we plan to expand our therapeutic areas from the central nervous system and ophthalmology fields to peripheral organs, enter overseas markets with Japan as a base, and transition from supplying single cells to providing 3D tissues and organs.
-
Number of programs
0
As of January 31, 2025
- Development Pipeline
-
Pre-clinical/Clinical Research Program
Pre-clinical/Clinical Research Program
| Cell type/Product code | Proposed indication | Region | Development stage |
|---|---|---|---|
| Photoreceptor (3D) (Allo iPS cell-derived) DSP-3077 |
Retinitis pigmentosa | Japan | Clinical research |
| Neural progenitor cells (Allo iPS cell-derived) |
Spinal cord injury | Japan | Clinical research |
| Nephron progenitor cells (organ) (Auto/ Allo iPS cell-based induced) |
Kidney failure | Japan, U.S. | Pre-clinical |